-
Product Insights
NewResponse Ortho Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Response Ortho Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Response Ortho, a subsidiary of WishBone Medical, develops, manufactures, and markets orthopedic products for bone fractures. It provides treatment for serious orthopedic issues namely, advanced fracture fixation and bone deformity correction. It also offers software solutions to improve the results in fracture fixation and anatomical alignment. The company's products include external fixators, intramedullary rods, plates, screws, and pins. Response Ortho...
-
Thematic Analysis
NewGlobalData’s AI Governance Framework – Thematic Intelligence
Reasons to buy ‘GlobalData’s AI Governance Framework’ thematic report: Get a comprehensive overview of GlobalData’s AI governance framework to identify all potential risks posed by AI systems and ensure the implementation of AI responsibly. Gain insights into the five core principles of responsible AI: transparency, accountability, safety, reliability, and social impact, as defined by GlobalData’s AI governance framework. Assist organizations in creating a checklist ensuring compliance with AI governance standards. How is our ‘AI Governance Framework’ report unique from other reports...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risankizumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risankizumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risankizumab in Ulcerative Colitis Drug Details: Risankizumab (Skyrizi) is a humanized...
-
Company Insights
NewDecoding Enel S.p.A. YouTube Advertising Strategy in Q1 2024​
The report on Enel S.p.A's advertising strategies on YouTube during the first quarter of 2024, focuses on key products such as Enel Formidable Photovoltaic and Enel Formidable Mobility. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Renewable Energy, Energy Storage, Solar Park and Energy Production. Moreover, the report examines the overarching themes of Innovation, Community Engagement, Social Responsibility, Environmental Impact and Clean Energy infused into these campaigns. By synthesizing these...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Head And Neck Cancer Drug Details: Olaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Osteosarcoma Drug Details: Olaparib (Lynparza) is an antineoplastic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Laryngeal Cancer Drug Details: Olaparib (Lynparza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Oropharyngeal Cancer Drug Details: Olaparib (Lynparza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Adenocarcinoma Of The Gastroesophageal Junction Drug...